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Transforming growth factor-b1 increases albumin permeability
of isolated rat glomeruli via hydroxyl radicals
RAM SHARMA, ASHWANI KHANNA, MUKUT SHARMA, and VIRGINIA J. SAVIN
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Transforming growth factor-b1 increases albumin permeability by cells in a high molecular weight latent form, and
of isolated rat glomeruli via hydroxyl radicals. its three components are (1) mature biologically active
Background. Transforming growth factor-b1 (TGF-b1) is a TGF-b, (2) latency-associated peptide (LAP), and (3)multifunctional cytokine. Glomerular cells and tubular epithe-
latent TGF-b–binding protein (LTBP) [3].lial cells secrete and respond to TGF-b1. A close association
Transforming growth factor-b exists in three isoformsbetween elevated levels of TGF-b1 and the development of
glomerulonephritis, glomerulosclerosis, and tubular hypertro- (TGF-b1, TGF-b2, and TGF-b3) with 65 to 85% homol-
phy has been documented. The role of TGF-b1 in proteinuria ogy. No discrete function for a specific isoforms has been
is not well understood. identified [2]. Genes encoding TGF-b are located onMethods. Isolated rat glomeruli were incubated in medium
three distinct chromosomes, are 100 kb (7 exons) in sizealone or with TGF-b1 (1 to 10 ng/mL) and TGF-b1 1 200
with binding sites for transcription factors, and autoregu-U/mL of superoxide dismutase (SOD) or 1 mmol/L of dimeth-
ylthiourea (DMTU) scavengers of superoxide and hydroxyl late their synthesis [4]. All three isoforms of TGF-b
radicals, respectively, for up to 60 minutes at 378C. Glomerular (TGF-b1, TGF-b2, and TGF-b3) have been localized in
albumin permeability (Palb) was calculated from the volumetric kidneys, and their increased expression in human glo-response of glomeruli to an oncotic gradient using videomicros-
merulonephritis has been documented [5]. Increased ex-copy.
Results. One or 2.5 ng/mL of TGF-b1 had no effect on Palb pression of TGF isoforms and accumulation of ECM in
(0.18 6 0.08, N 5 17; 0.18 6 0.079, N 5 20 vs. control 0.00 6 acute and chronic renal transplant rejection have also
0.06, N 5 25), whereas 5 or 10 ng/mL of TGF-b1 caused a been documented [6]. In numerous studies of experimen-
significant increase in Palb (0.31 6 0.09, N 5 20; 0.33 6 0.06, tal and human kidney diseases, TGF-b1 has been identi-N 5 23) within 15 minutes. The effect of 10 ng/mL of TGF-b1
fied as a key mediator of glomerulosclerosis [7].on Palb increased further after 30, 45, or 60 minutes of incubation
(0.43 6 0.06, N 5 24; 0.53 6 0.06, N 5 25; 0.74 6 0.075, N 5 The biological effects of TGF-b1 are mediated by
21). The TGF-b1–induced increase in Palb (0.75 6 0.065, N 5 binding to specific cell membrane receptor proteins.
15) was blocked by SOD (0.07 6 0.14 N 5 15) or by DMTU Three types (I, II, and III) of TGF-b receptors have(0.04 6 0.13, N 5 15). Incubation of glomeruli with the carrier
been identified [2, 8]. Types I and II are 53 and 75 kDmedium (4N HCl) in which TGF-b1 is dissolved and SOD or
glycoproteins, have serine threonine kinase activity inDMTU alone did not affect Palb.
Conclusion. Elevated levels of TGF-b1 derived from glo- their cytoplasmic domains, and are present on all cells
merular or extraglomerular sources are capable of increasing [9–12]. Type III receptor is a 280 to 330 kD proteoglycan
glomerular Palb via superoxide and hydroxyl radicals and may with a short cytoplasmic domain [13]. Type I is involvedlead to proteinuria in vivo.
in synthesis of matrix, type II in inhibition of growth, and
type III in promoting the binding of TGF-b to receptors.
Increased expression of all three types of TGF-b recep-Transforming growth factor-b (TGF-b) is a multifunc-
tors in kidney sections from human glomerulonephritistional cytokine involved in the regulation of cell prolifer-
patients has been documented [14].ation, differentiation, extracellular matrix (ECM) syn-
Elevated levels of TGF-b1 have been associated withthesis, and immune response [1, 2]. TGF-b is secreted
the glomerulonephritis [15], glomerulosclerosis or inter-
stitial fibrosis [16], tubulogenesis [17], and tubular hyper-
trophy [18]. However, it is still unknown whetherKey words: reactive oxygen species, glomerular albumin permeability,
cytokine, proteinuria. TGF-b1 plays a causative role in proteinuria. In the
present study, we examined the direct effect of TGF-b1Received for publication July 23, 1999
on the glomerular filtration barrier and examined theand in revised form November 11, 1999
Accepted for publication February 1, 2000 role of reactive oxygen species (ROS) using in vitro
measurements of glomerular albumin permeability (Palb).Ó 2000 by the International Society of Nephrology
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METHODS
Experimental animals
Normal male Sprague-Dawley rats (180 to 250 g body
weight) maintained on Purina chow and water ad libitum
were used in all experiments.
TGF-b1 and reactive oxygen species scavengers
Human recombinant TGF-b1 was kindly supplied by
Dr. Anita Roberts (National Institutes of Health, Beth-
esda, MD, USA). The biological activity of this TGF-b1
was measured in vitro by mink lung epithelial cell line
assay, where a 50% inhibition was observed with 200
pmol/L (5 ng/mL) of TGF-b1. We have also tested the
in vivo activity of this TGF-b1 [19]. The concentration
used in most experiments was 10 ng/mL, which is within
the physiologic range of the cytokine and is comparable Fig. 1. Effect of various amounts of transforming growth factor-b1
(TGF-b1) on glomerular albumin permeability (Palb). Rat glomerulito those used in other in vitro biological assays. ROS
were incubated with or without 1 to 10 ng/mL of TGF-b1 for 15 minutesscavengers, superoxide dismutase (SOD) and dimethyl- at 378C, and Palb was measured. As shown, 1 and 2.5 ng/mL of TGF-b1
thiourea (DMTU), and all other chemicals used in this had very little effect on Palb (N 5 17 and 20, respectively) compared
with control glomeruli (N 5 25). As shown, 5 and 10 ng/mL of TGF-b1study were obtained from Sigma Chemical Co. (St. Louis,
caused a significant increase (*P , 0.01) in Palb (N 5 20 and 23, respec-MO, USA). We used an excess amount of SOD (200 tively).
U/mL) and DMTU (1 mmol/L) to completely scavenge
the superoxide or hydroxyl ion generated by TGF-b1.
Effect of TGF-b1 on glomerular albumin permeability nonperfused glomeruli exhibit a volumetric response to
As described previously, glomeruli from Sprague- oncotic gradients. There is a direct relationship between
Dawley rats were isolated in medium containing 4 g/dL the increase in glomerular volume (DV) and the oncotic
bovine serum albumin (BSA) [20]. In the first series of gradient (Dp) applied across the capillary wall. In the
experiments, glomeruli were incubated with or without current studies, salb 5 (DVexperimental/DVcontrol). Convectional
TGF-b1 (1 to 10 ng/mL) for 15 to 60 minutes at 378C. permeability (Palb) is defined as Palb 5 (1 2 salb).In another set of experiments, glomeruli were incubated
with TGF-b1 (10 ng/mL) alone or with 200 U SOD or Statistics
with 1 mmol/L of DMTU for 45 minutes at 378C. We
Average salb and Palb were calculated for glomeruli inalso incubated some of the glomeruli with the carrier
each experimental condition, and values were comparedmedium (4N HCl) in which TGF-b1 was dissolved as a
using analysis of variance. Correlation coefficients werecontrol for 45 minutes at 378C.
calculated from average values for each experimental
Measurement of glomerular volume change condition. All values are expressed as mean 6 SEM. P
values , 0.05 were considered significant.After experimental treatment and incubation, glomer-
uli were allowed to adhere to coverslips coated with
poly l-lysine (1 mg/mL) for 10 to 15 seconds. Images of
RESULTSadherent glomeruli were recorded using videomicros-
copy. The initial medium was then replaced with fresh Effect of TGF-b1 on glomerular Palb
medium of lower oncotic pressure. Volume changes in Glomeruli were incubated with various concentrations
glomeruli consequent to the applied oncotic gradient
of TGF-b1 (1, 2.5, 5, and 10 ng/mL) for 15 minutes atoccurred within five seconds. Initial and final volumes
378C, and Palb was calculated. As shown in Figure 1,of each glomerulus were calculated from the average
TGF-b1 at concentrations of 1 or 2.5 ng/mL had no effectdiameter measured from the recorded images. Volume
on Palb (0.18 6 0.08, N 5 17; 0.18 6 0.08, N 5 20)change (DV) was calculated as DV 5 (Vfinal 2 Vinitial/
compared with control (0.00 6 0.07, N 5 25). A signifi-Vfinal) 3 100. At least five glomeruli from each of three
cant increase in Palb by TGF-b1 was evident at concentra-to five rats were studied in each experimental condition.
tions of 5 or 10 ng/mL (0.31 6 0.09, N 5 20, and 0.33 6
Use of volume change to calculate salb 0.06, N 5 23, respectively) within 15 minutes. In other
experiments, glomeruli were incubated with 10 ng/mLThe rationale and calculations for the measurement of
salb have been detailed in an earlier report [20]. Isolated of TGF-b1 for 5, 15, 30, 45, and 60 minutes. As shown
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Fig. 2. Time course of TGF-b1–mediated increase in glomerular Palb.
Rat glomeruli were incubated with 10 ng/mL of TGF-b1 for up to 60
minutes, and the increase in Palb was measured. TGF-b1 10 ng/mL
caused a significant increase in Palb (*P , 0.01) within 15 minutes (N 5
23), and this effect of TGF-b1 increased further at 30 (N 5 24), 45
(N 5 25), and 60 minutes (N 5 21) of incubation.
in Figure 2, 10 ng/mL of TGF-b1 caused a significant
increase in Palb within 15 minutes (0.33 6 0.06, N 5 23,
vs. control 0.00 6 0.070, N 5 25), and this effect increased
further in 30, 45, or 60 minutes of incubation at 378C
(0.43 6 0.06, N 5 24; 0.53 6 0.06, N 5 25; and 0.74 6
0.075, N 5 21, respectively).
Fig. 3. Effect of reactive oxygen species (ROS) scavengers on TGF-b1
Effect of oxygen radical scavengers on mediated increase in glomerular Palb. Rat glomeruli were incubated in
isolation medium, in control medium (4N HCl), with 10 ng/mL ofTGF-b1–mediated increase in Palb
TGF-b1 and TGF-b1 1 SOD, or DMTU and SOD or DMTU alone
Further experiments were carried out to determine for up to 60 minutes. (A) TGF-b1 caused a significant increase (*P ,
0.01) in Palb (N 5 15), and SOD (200U/mL) blocked this effect (N 5whether ROS were involved in the TGF-b1–mediated
15; shown by two asterisks. Four N HCl and SOD alone had no effectincrease in Palb. Glomeruli were incubated with TGF-b1 on Palb (N 5 15 and N 5 22, respectively). (B) TGF-b1 caused a
alone, TGF-b1 carrier medium (4N HCl), or TGF-b1 significant increase (*P , 0.01) in Palb (N 5 15), and 1 mmol/L of
DMTU (N 5 15) also blocked the TGF-b1–mediated increase in Palb,and ROS scavengers (SOD and DMTU). As shown in
as shown by two asterisks, and DMTU alone had no effect on PalbFigure 3A, TGF-b1 (10 ng/mL) induced an increase in (N 5 15).
Palb with in 60 minutes (0.75 6 0.06, N 5 15, vs. control
0.00 6 0.086, N 5 14), and this effect was blocked by
SOD (0.07 6 0.14, N 5 15). Incubations of glomeruli
scavenger of superoxide, and DMTU, a scavenger ofwith TGF-b1 carrier medium, 4N HCl (0.16 6 0.08, N 5
hydroxyl radical, abolished the TGF-b1–mediated in-15) and SOD alone had no effect (0.06 6 0.02, N 5 22)
crease in Palb. These results implicate the hydroxyl radi-on Palb. As shown in Figure 3B, a TGF-b1–mediated
cals as important mediators in the effect of TGF-b1increase in Palb was also blocked by 1 mmol/L of DMTU
on Palb.(0.14 6 0.13, N 5 15), whereas DMTU alone had no
Proteinuria is a nonspecific manifestation of glomeru-effect (0.17 6 0.07, N 5 15) on Palb.
lar injury and is seen in systemic and renal diseases that
are characterized by inflammation or elevated cytokine
DISCUSSION production such as platelet-activating factor (PAF) [21],
tumor necrosis factor-a (TNF-a) [22], and TGF-b [23].Transforming growth factor-b1 significantly increased
the Palb of isolated rat glomeruli in this study. As little TGF-bs are homodimeric peptide growth factors with a
molecular weight of 25 kD [2, 4]. TGF-bs are secretedas 5 ng/mL of TGF-b1 increased Palb within 15 minutes.
The effect of TGF-b1 on Palb was dose and time depen- by cells in a high molecular weight latent form, and
their activation in vitro can be achieved by acidification,dent. Incubation with 10 ng/mL of TGF-b1 for 45 min-
utes caused the maximal response in this study. SOD, a alkalization, and by proteases [3]. The latent form of
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TGF-b is composed of three components: (1) mature generated by either xanthine/xanthine oxidase system or
by phorbol myristate acetate (PMA)-activated macro-biologically active TGF-b of 25 kD, (2) LAP, and (3)
LTBP [3]. There are two kinds of TGF-b1, the large phages increases Palb of isolated glomeruli, and this effect
is abrogated by SOD but not catalase. These resultslatent form with LTBP and small latent form without
LTBP. Tubular cells secrete small latent TGF-b1, while indicate that superoxide is the mediator of proteinuria
[46]. We have also shown that incubation of isolatedglomerular cells secrete large latent TGF-b1 [24].
Elevated levels of circulating TGF-b1 have been impli- glomeruli with PMA-activated rat polymorphonuclear
cells increased Palb, and this increase is prevented bycated in the pathogenesis of tissue fibrosis in patients
with advanced breast cancer [25] and thrombotic throm- catalase, SOD, taurine, or sodium azide, implicating hy-
pohalous acid as the mediator of proteinuria [47].bocytopenic purpura [26]. Additionally, enhanced renal
expression of TGF-b1 protein and mRNA has been re- Resident glomerular cells are capable of ROS produc-
tion. Glomerular epithelial cells in culture produce ROSported in a range of glomerular diseases in both animal
models [27–29] and in human disease [30, 31]. A close in response to various toxins such as doxorubicin and
PAN [48, 49]. Mesangial cells in culture produce ROSassociation between elevated expression of TGF-b1 and
development of glomerulonephritis [15], glomeruloscle- in response to immune complexes [50], PMA, PAF [51],
and TNF-a [52]. Augmented production of ROS byrosis/interstitial fibrosis [16], tubulogenesis [17] and tu-
bular cell hypertrophy [18] and tubular cell dysfunction TGF-b1 in Hamester pancreatic beta-cell line HIT cells
[53], in fetal hepatocytes [54], and in human lung fibro-[32] have been shown. Suppression of experimental glo-
merulonephritis by anti–TGF-b1 antiserum has also blasts [55] has been shown. The current results are consis-
tent with the idea that TGF-b1 can also induce produc-been shown [33]. In transgenic mice, increased levels
of circulating TGF-b1 induced glomerular disease and tion of ROS by glomerular cells and thus can alter Palb.
It is unlikely that new protein formation by glomerularproteinuria [34].
Transforming growth factor-b1 acts on glomerular cells or marked structural change of cells or basement
membrane is responsible for the increase in Palb inducedcells in several ways. TGF-b1 stimulates production of
ECM accumulation by glomerular epithelial cells [35], by TGF-b1 in light of the short time of incubation. An
mesangial cells [36], and tubular epithelial cells [37]. The increase in the message of collagen and fibronectin can
induction of ECM accumulation in these cells by TGF-b1 be demonstrated only after four hours of incubation of
is achieved by three distinct mechanisms: (1) induction glomerular epithelial cells with TGF-b1. We postulate
of transcription, synthesis, and secretion of matrix com- that glomerular exposure to TGF-b1 stimulates the pro-
ponents, (2) decrease synthesis of protease’s and increase duction of ROS, specifically superoxide and hydroxyl
in synthesis of protease inhibitors, and (3) increasing radicals, by mesangial cells or glomerular epithelial cells
transcription and membrane expression of adhesion mol- (GECs). ROS may then alter the properties of the GEC
ecules (integrins) that regulate matrix assembly [2]. membrane, cytoskeleton, and/or intercellular junctions
TGF-b1 stimulates mesangial cell proliferation through possibly by lipid peroxidation or may induce the produc-
expression of platelet-derived growth factor protein and tion of other mediators such as eicosanoids, cyclic nucle-
receptor [38]. TGF-b1 also inhibits production of in- otides, or cytokines, leading to increased Palb in the exper-
flammatory molecules such as interleukin-1 and induc- imental situation. Direct effects of TGF-b1 on the
ible nitric oxide synthase [39]. TGF-b1 causes mesangial filtration barrier through a ROS mediator may explain
cell hypertrophy by inhibiting cell proliferation while proteinuria seen in settings of increased circulating
increasing protein synthesis [40]. TGF-b1 by infiltrating inflammatory cells and diseases
There is ample evidence that ROS are crucial media- with increased intrinsic glomerular TGF-b1 such as glo-
tors in inflammatory and noninflammatory glomerular merulonephritis. We conclude that TGF-b1 is capable
disease [41]. Production of ROS is associated with in- of affecting the glomerular filtration barrier directly with-
creased Palb in several animal models [42], and blocking out the involvement of secondary hemodynamic and im-
the effects of these mediators with scavengers is associ- munologic effects, and that the TGF-b1–mediated in-
ated with improvement of proteinuria [43]. Wang et al crease in glomerular Palb is independent of its effects on
showed that treatment of puromycin aminonucleoside cell proliferation or on matrix synthesis.
(PAN) nephrosis rats with cyclosporine A decreased
proteinuria; treated rats also showed higher activities of ACKNOWLEDGMENTS
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